Search Result

Results for "

mental

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (21) Adrenergic Receptor (9) Amyloid-β (1) Apoptosis (4) Autophagy (4) Biochemical Assay Reagents (3) Cannabinoid Receptor (1) CFTR (1) Cholecystokinin Receptor (1) CRFR (1) DNA Methyltransferase (1) Dopamine Receptor (27) Drug Derivative (4) Drug Intermediate (2) Drug Metabolite (5) Endogenous Metabolite (1) Environmental Pollutants (1) FKBP (1) GABA Receptor (2) Glucocorticoid Receptor (4) HCN Channel (1) Histamine Receptor (9) Isotope-Labeled Compounds (6) mAChR (5) mGluR (1) MMP (1) Monoamine Oxidase (1) Neurokinin Receptor (1) Neurotensin Receptor (1) Oxytocin Receptor (1) Progesterone Receptor (3) PROTACs (1) Ras (1) Reference Standards (6)
By Research Areas:	Cancer (10) Cardiovascular Disease (5) Endocrinology (3) Infection (3) Inflammation/Immunology (9) Metabolic Disease (5) Neurological Disease (75)

By Targets:

5-HT Receptor (21)

Adrenergic Receptor (9)

Amyloid-β (1)

Apoptosis (4)

Autophagy (4)

Biochemical Assay Reagents (3)

Cannabinoid Receptor (1)

CFTR (1)

Cholecystokinin Receptor (1)

CRFR (1)

DNA Methyltransferase (1)

Dopamine Receptor (27)

Drug Derivative (4)

Drug Intermediate (2)

Drug Metabolite (5)

Endogenous Metabolite (1)

Environmental Pollutants (1)

FKBP (1)

GABA Receptor (2)

Glucocorticoid Receptor (4)

HCN Channel (1)

Histamine Receptor (9)

Isotope-Labeled Compounds (6)

mAChR (5)

mGluR (1)

MMP (1)

Monoamine Oxidase (1)

Neurokinin Receptor (1)

Neurotensin Receptor (1)

Oxytocin Receptor (1)

Progesterone Receptor (3)

PROTACs (1)

Ras (1)

Reference Standards (6)

By Research Areas:

Cancer (10)

Cardiovascular Disease (5)

Endocrinology (3)

Infection (3)

Inflammation/Immunology (9)

Metabolic Disease (5)

Neurological Disease (75)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-A0077

Perphenazine 3 Publications Verification	Dopamine Receptor Histamine Receptor 5-HT Receptor Adrenergic Receptor Apoptosis Autophagy	Neurological Disease Inflammation/Immunology Endocrinology Cancer
Perphenazine is an orally active dopamine receptor and histamine-1 receptor antagonist, with K_i values of 0.56 nM (D2), 0.43 nM (D3), 6 nM (5-HT2A), respectively. Perphenazine also binds to Alpha-1A adrenergic receptor. Perphenazine inhibits cancer cell proliferation, and induces apoptosis. Perphenazine can be used in the research of mental disease, cancer, inflammation .

HY-B1069

Molsidomine 1 Publications Verification SIN-10; Morsydomine	Drug Metabolite	Cardiovascular Disease Neurological Disease Metabolic Disease
Molsidomine, a nitric oxide (NO) donor, is an orally active vasodilator agent. Molsidomine is a prodrug that can be rapidly metabolized in the liver to its active metabolite, Linsidomine (HY-101200). Molsidomine can be used for the study of angina pectoris, mental disorders and diabetic complications .

HY-B1834

Megestrol	Progesterone Receptor Glucocorticoid Receptor	Infection Neurological Disease Inflammation/Immunology Cancer
Megestrol is an orally active glucocorticoid and progesterone receptor agonist. Megestrol can alleviate anorexia, cachexia or unexplained significant weight loss associated with acquired immunodeficiency syndrome (AIDS). Megestrol may cause manifestations similar to those of glucocorticoids and increase the risk of mental disorders .

HY-136379

CID44216842 2 Publications Verification Cdc42-IN-1	Ras	Cancer
CID44216842 (Cdc42-IN-1) is a potent Cdc42-selective guanine nucleotide binding lead inhibitor. The EC₅₀s for Cdc42 WT and Cdc42Q61L mutant are 1.0 and 1.2 μM in GTP binding assay, respectively. The EC₅₀s for Cdc42 WT and Cdc42Q61L mutant are 0.3 and 0.5 μM in GDP binding assay, respectively. Use as a molecular probe .

HY-132806

Alogabat RG-7816; RO-7017773	GABA Receptor	Neurological Disease
Alogabat is a positive allosteric modulator (PAM) and agonist (K_i <100 nM) of the GABAA α5 receptor, targeting the α5β3γ2 subunit with a Ki of 8.7 nM. Alogabat increases the expression level of α5β3γ2 in oocytes (1.97-fold). GABAA has been implicated in cognitive impairment associated with central nervous system (CNS) disorders, brain cancer (including brain tumors such as medulloblastoma), and can be used in the study of mild cognitive impairment (MCI), amnestic MCI (aMCI), age-associated memory impairment (AAMI), age-related cognitive decline (ARCD), dementia, Alzheimer's disease (AD), prodromal AD, post-traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cognitive impairment associated with cancer treatment, mental retardation, Parkinson's disease (PD), autism spectrum disorder, fragile X, Rett syndrome, obsessive-compulsive behavior, and substance addiction .

HY-100703

Pipamperone Floropipamide; McN-JR 3345; R 3345	5-HT Receptor Dopamine Receptor	Neurological Disease
Pipamperone (Floropipamide) is a butyrophenone derivative and high-affinity antagonist of 5-HT_2A receptor (pK_i=8.2) and D₄ receptor (pK_i=8.0). Pipamperone is also a low-affinity antagonist of D₂ receptor (pK_i=6.7). Pipamperone affects neurotransmitter functions and exerts antipsychotic activity. Pipamperone is used in the research of mental disorders such as autism-related behavioral disorders and Alzheimer's disease .

HY-W021265

Cyclohexane-1,2,3,4,5,6-hexaol Cyclohexane-1,2,3,4,5,6-hexol	Biochemical Assay Reagents	Others
Cyclohexane-1,2,3,4,5,6-hexaol, also known as inositol or inositol, is a cyclic sugar alcohol consisting of a six-carbon ring with six hydroxyl groups. This compound is important for its biological activity and is widely distributed in nature, especially in plant and animal tissues. It plays a role in various physiological processes such as signal transduction, osmoregulation and lipid metabolism. In addition, Cyclohexane-1,2,3,4,5,6-hexaol has potential investigational effects, including improving conditions related to insulin resistance, polycystic ovary syndrome, and mental health conditions. It can also be used as a supplement in animal feed and human nutritional products.

HY-W010265

Butyrophenone 1-Phenylbutan-1-one; 1-Phenyl-1-butanone	Environmental Pollutants Dopamine Receptor	Neurological Disease
Butyrophenone (1-Phenylbutan-1-one) is a dopamine receptor (DA Receptor) antagonist and can be used in research on mental disorders .

HY-U00051

Propiomazine	Histamine Receptor Dopamine Receptor	Neurological Disease
Propiomazine is an orally active antihistamine agent. Propiomazine is a potent prolactin (PRL) release stimulant, whose effect depends on the antagonism of the dopaminergic system and can inhibit the secretion of luteinizing hormone (LH). Propiomazine is mainly used for anesthesia assistance, mental disorders and anxiety-induced sedation, and can also be used in research related to insomnia .

HY-W100249

MMAI 5-Methoxy-6-methyl-2-aminoindan	5-HT Receptor	Neurological Disease
MMAI is a selective serotonin releaser that can be used in the research of mental illnesses .

HY-W094464

Lithium sulfate	Biochemical Assay Reagents	Neurological Disease
Lithium sulfate is an inorganic compound that can improve the cycling life and efficiency of a 2 V/20 A H lead-acid battery. Lithium sulfate can be used to study mental illnesses .

HY-13340

VU0152100 1 Publications Verification VU152100	mAChR	Neurological Disease
VU0152100 (VU152100) is a highly selective mAChR positive allosteric modulator (permeable to the blood-brain barrier). VU0152100 reverses Amphetamine-induced hypermotility in rats and increased levels of extracellular dopamine in nucleus accumbens and caudate-putamen. VU0152100 has good research potential in psychosis and cognitive impairment associated with mental disorders such as schizophrenia .

HY-P2283

β-Amyloid (1-37) (human)	Amyloid-β	Neurological Disease
β-Amyloid (1-37) (human) correlates moderately with Mini-Mental State Examination (MMSE) scores in Alzheimer disease. β-Amyloid (1-37) (human) possesses an added diagnostic value .

HY-W009754

Antidepressant agent 10	5-HT Receptor	Neurological Disease
Antidepressant agent 10 (Compound 4) is an orally active compound. Antidepressant agent 10 has IC₅₀ values of 190 nM and 110 nM for 5-HT_1A and 5-HT₂, respectively. Antidepressant agent 10 can be used in the research of mental disorders .

HY-W010625

Lithium 2-hydroxypropanoate 35+ Cited Publications	Biochemical Assay Reagents	Neurological Disease Inflammation/Immunology
Lithium 2-hydroxypropanoate is a lithium salt. Lithium 2-hydroxypropanoate has immunomodulatory activity (slightly enhancing PHA (HY-N7038)-induced lymphocyte proliferation). Lithium 2-hydroxypropanoate can be used in antioxidant activity assays. Lithium 2-hydroxypropanoate can be used in the research of mental diseases .

HY-Y0588

Carbobenzoxyproline L-Cbz-Proline	MMP	Others
Carbobenzoxyproline (L-Cbz-Proline) is an inhibitor of prolidase. Carbobenzoxyproline can be used for prolidase deficiency (PD) research .

HY-103564

ACDPP	mGluR	Neurological Disease
ACDPP is a specific mGluR5 antagonist. ACDPP partially bolcks the increase of fragile X mental retardation protein (FMRP) caused by DHPG (HY-12598A) (group I mGluR Agonist) .

HY-A0163A

Clopenthixol	Dopamine Receptor	Neurological Disease
Clopenthixol is a thiaquinoline compound with inhibitory effects similar to those of phenothiazine antipsychotics. Clopenthixol is an antagonist of D1 and D2 dopamine receptors. Clopenthixol is mainly used to suppress schizophrenia and other mental disorders .

HY-107434

Molindone (±)-Molindone; SPN-810M	Dopamine Receptor	Neurological Disease
Molindone ((±)-Molindone), an indole derivative, is a potent dopamine D2 and D5 receptor antagonist. Molindone ((±)-Molindone) can be used for the research of schizophrenia and severe mental illness .

HY-14753

Rosonabant	Cannabinoid Receptor	Cardiovascular Disease Metabolic Disease
Rosonabant is a selective antagonist for cannabinoid receptor (CB1 receptor), which reduces body weight and improves improves the risk of obesity-related cardiovascular metabolic diseases. Rosonabant exhibits adverse side effect, such as nausea and mental disorder .

HY-119918

Cycrimine	mAChR	Neurological Disease
Cycrimine is an orally active muscarinic cholinergic receptor (mAChR) M1 antagonist, reduces the acetylcholine levels in parkinson model. Cycrimine shows antispasmodic activity, can be used in studies of behavioral and mental disorder .

HY-77910

4-(4-Bromophenyl)-4-hydroxypiperidine BPHP	Drug Metabolite	Neurological Disease
4-(4-Bromophenyl)-4-hydroxypiperidine (BPHP) is a metabolite of Bromperidol (BRO) (HY-B0901) and is produced by N-dealkylation of BRO .

HY-W016323

2-Benzylaniline 2-Aminodiphenylmethane	Drug Intermediate	Neurological Disease
2-Benzylaniline is an intermediate. 2-Benzylaniline can be used to synthesize Compound 15. Compound 15 shows an affinity for the D₃ receptor with a K_i of 4654 nM. 2-Benzylaniline can be used in research on mental illnesses .

HY-G0003A

Milsaperidone (S)-Hydroxy Iloperidone; VHX-896	Drug Metabolite Dopamine Receptor 5-HT Receptor	Neurological Disease
Milsaperidone ((S)-Hydroxy Iloperidone) is an active metabolite of the antipsychotic agent Iloperidone (HY-17410). Milsaperidone is a dopamine D2 and 5-HT2A receptor antagonist. Milsaperidone rapidly converts to Iloperidone when taken orally. Milsaperidone can be used in the research of mental illnesses such as depression .

HY-177122

Raxlaprazine etomoxil	Dopamine Receptor	Neurological Disease
Raxlaprazine etomoxil is a small molecule compound with dopamine D2 and D3 receptor modulating activity, which has potential application value in research related to mental illnesses. Raxlaprazine etomoxil exhibits high affinity for human recombinant D2L receptors, with an inhibition constant (K_i) of 1.95 nM. Raxlaprazine etomoxil effectively inhibits forskolin-stimulated cAMP accumulation, with an half maximal effective concentration (EC₅₀) of 3.72 nM in functional activity experiments .

HY-162070

CCK antagonist 1	Cholecystokinin Receptor	Neurological Disease Cancer
CCK antagonist 1 (compound 3d) is a CCK antagonist with IC₅₀s of 1.1 μM and 4 μM for CCK1 and CCK2, respectively. CCK antagonist 1 can be used for research of cancer and mental disease .

HY-W1123900

5-HT2A agonist 3	5-HT Receptor	Neurological Disease
5-HT2A agonist 3 (Compound P-141) is a selective 5-hydroxytryptamine 2A receptor (5-HT_2A) agonist with an EC₅₀ value of 13.80 nM. 5-HT2A agonist 3 is promising for research of mental illnesses such as depression, post-traumatic stress disorder, obsessive-compulsive disorder, and central nervous system disorders .

HY-P2204

PD-149163	Neurotensin Receptor	Neurological Disease Inflammation/Immunology
PD-149163 is an NTR-1 agonist. PD-149163 reverses intestinal damage through its anti-inflammatory, antioxidant, and cell proliferation promoting properties. PD-149163 has antipsychotic effects. PD-149163 is commonly used in research on mental illness and intestinal injury .

HY-A0077A

Perphenazine dihydrochloride	Dopamine Receptor Histamine Receptor 5-HT Receptor Adrenergic Receptor Apoptosis Autophagy	Neurological Disease Inflammation/Immunology Endocrinology Cancer
Perphenazine dihydrochloride is an orally active dopamine receptor and histamine-1 receptor antagonist, with K_i values of 0.56 nM (D2), 0.43 nM (D3), 6 nM (5-HT2A), respectively. Perphenazine dihydrochloride also binds to Alpha-1A adrenergic receptor. Perphenazine dihydrochloride inhibits cancer cell proliferation, and induces apoptosis. Perphenazine dihydrochloride can be used in the research of mental disease, cancer, inflammation .

HY-168537

LB-102	Dopamine Receptor 5-HT Receptor	Neurological Disease
LB-102 is an orally active inhibitor of dopamine D₂, D₃, and 5-HT7 receptors, which can be used in research on schizophrenia and other psychiatric disorders .

HY-177313

AAG561 NVP-AAG 561	CFTR	Neurological Disease
AAG561 is a corticotropin-releasing factor receptor 1 (CRF1) antagonist. AAG561 can be used for the study of the underlying emotion dysregulation of a mental disease or disorder .

HY-177101

Luvesilocin RE-104; FT-104	5-HT Receptor	Neurological Disease
Luvesilocin (Example 6) is a tryptamine prodrug. Luvesilocin can convert into an active form, acting as a 5HT2A agonist in vivo upon administration. Luvesilocin can be studied in research for mental diorders .

HY-100703A

Pipamperone dihydrochloride Floropipamide dihydrochloride; McN-JR 3345 dihydrochloride; R 3345 dihydrochloride	Dopamine Receptor 5-HT Receptor	Neurological Disease
Pipamperone dihydrochloride (Floropipamide dihydrochloride) is a butyrophenone derivative and high-affinity antagonist of 5-HT_2A receptor (pK_i=8.2) and D₄ receptor (pK_i=8.0). Pipamperone dihydrochloride is also a low-affinity antagonist of D₂ receptor (pK_i=6.7). Pipamperone dihydrochloride affects neurotransmitter functions and exerts antipsychotic activity. Pipamperone dihydrochloride is used in the research of mental disorders such as autism-related behavioral disorders and Alzheimer's disease .

HY-U00244

Benzquinamide P2647; BZQ; Benzoquinamide	Adrenergic Receptor Dopamine Receptor	Metabolic Disease
Benzquinamide (P2647; BZQ; Benzoquinamide) is an orally active binder of dopamine receptors and adrenergic receptors. Benzquinamide specifically targets dopamine D2, D3, D4 receptors and α-2A, α-2B, α-2C adrenergic receptors. Benzquinamide regulates blood pressure and heart rate, attenuates the pressor effect of adrenaline, and exhibits activities such as antiemesis, anxiolysis, and reduction of histamine-induced bronchoconstriction. Benzquinamide has good safety and does not deplete serotonin or norepinephrine in the brain. Benzquinamide can be used in studies related to nausea/vomiting, mental disorders, anxiety states, neurosis, and psychosis .

HY-115896

Zuclopenthixol decanoate	Others	Neurological Disease
Zuclopenthixol decanoate is a long-acting agent for schizophrenia and other serious mental illnesses research .

HY-W010265R

Butyrophenone (Standard) 1-Phenylbutan-1-one (Standard); 1-Phenyl-1-butanone (Standard)	Reference Standards Dopamine Receptor	Neurological Disease
Butyrophenone (Standard) is the analytical standard of Butyrophenone. This product is intended for research and analytical applications. Butyrophenone (1-Phenylbutan-1-one) is a dopamine receptor (DA Receptor) antagonist and can be used in research on mental disorders .

HY-139035

CRHR1 antagonist 1	CRFR	Neurological Disease
CRHR1 antagonist 1 (compound 10a) is a non-peptide corticotropin-releasing hormone type 1 receptor (CRHR1) antagonist. CRHR1 antagonist 1 can be utilized in mental disorders research .

HY-N12134

Methyl piperate	Monoamine Oxidase	Neurological Disease
Methylpiperic acid is a piperine alkaloid with significant MAO inhibitory activity (IC₅₀3.6 μM). Methylpiperic acid is less effective against MAO-B (IC 501.6 μM) than MAO-A (IC₅₀27.1 μM) has a bidirectional inhibitory effect. Methylphenidate is used to research mental disorders .

HY-174909

5-HT2A receptor agonist-11	5-HT Receptor	Neurological Disease
5-HT2A receptor agonist-11 (Compound I-69) is a 5-HT2A receptor agonist with an EC₅₀ of 22 nM. 5-HT2A receptor agonist-11 can be used in the research of mental illness or central nervous system disorders .

HY-160978

Timelotem KC-7507 free base	GABA Receptor	Neurological Disease
Timelotem (KC-7507 free base) is a representative of a class of 1, 2-cyclo1, 4-benzodiazepines. Timelotem shows significant antipsychotic properties. Timelotem produces sedative, anti-anxiety and anti-convulsant effects by enhancing the action of the neurotransmitter gamma-aminobutyric acid (GABA). Timelotem can be used in studies of schizophrenia and other mental disorders .

HY-149704

M1/M2/M4 muscarinic agonist 1	mAChR	Neurological Disease
M1/M2/M4 muscarinic agonist 1 (Compound 42) is a muscarinic M4/M1/M2 agonist with EC₅₀ values of 6.5, 26 and 210 nM for M4/M1/M2, respectively. M1/M2/M4 muscarinic agonist 1 can be used for research on mental diseases, such as schizophrenia, delusion, etc .

HY-176721

5-HT2A receptor agonist-10	5-HT Receptor	Neurological Disease
5-HT2A receptor agonist-10 (Compound (R)-I-121.HCl) is a 5-HT2A receptor agonist, with an IC₅₀ of 2192.39 nM for h5-HT2A and h5-HT1A, respectively. 5-HT2A receptor agonist-10 can be used for the research of psychosis, mental illnesses and CNS disorders .

HY-13340R

VU0152100 (Standard) VU152100 (Standard)	mAChR Reference Standards	Neurological Disease
VU0152100 (Standard) is the analytical standard of VU0152100. This product is intended for research and analytical applications. VU0152100 (VU152100) is a highly selective mAChR positive allosteric modulator (permeable to the blood-brain barrier). VU0152100 reverses Amphetamine-induced hypermotility in rats and increased levels of extracellular dopamine in nucleus accumbens and caudate-putamen. VU0152100 has good research potential in psychosis and cognitive impairment associated with mental disorders such as schizophrenia .

HY-A0077R

Perphenazine (Standard)	Reference Standards Dopamine Receptor Histamine Receptor 5-HT Receptor Adrenergic Receptor Apoptosis Autophagy	Neurological Disease Inflammation/Immunology Endocrinology Cancer
Perphenazine (Standard) is the analytical standard of Perphenazine. This product is intended for research and analytical applications. Perphenazine is an orally active dopamine receptor and histamine-1 receptor antagonist, with K_i values of 0.56 nM (D2), 0.43 nM (D3), 6 nM (5-HT2A), respectively. Perphenazine also binds to Alpha-1A adrenergic receptor. Perphenazine inhibits cancer cell proliferation, and induces apoptosis. Perphenazine can be used in the research of mental disease, cancer, inflammation .

HY-130689

Pinoxepin hydrochloride	Endogenous Metabolite	Neurological Disease
Pinoxepin hydrochloride is an antipsychotic drug with sedative and antidepressant activities. Pinoxepin hydrochloride is used to suppress mental disorders such as schizophrenia and depression. Pinoxepin hydrochloride also has the effect of improving sleep quality .

HY-107693

SSR 146977 hydrochloride	Neurokinin Receptor	Neurological Disease Inflammation/Immunology
SSR 146977 hydrochloride is a potent and selective antagonist of the tachykinin NK₃ receptor. SSR 146977 hydrochloride can be used in the study of psychiatric disorders and airway inflammation .

HY-154867

DNMT2-IN-1	DNA Methyltransferase	Cancer
DNMT2-IN-1 (compound 80) is a potent and selective DNMT2 (DNA methyltransferase 2) inhibitor with an IC₅₀ value of 1.2 μM, and has the potential for mental and metabolic disorders or cancer research .

HY-W704749

7-Hydroxychlorpromazine hydrochloride	Drug Metabolite Dopamine Receptor	Neurological Disease
7-Hydroxychlorpromazine hydrochloride is the active metabolite of Chlorpromazine (HY-12708). 7-Hydroxychlorpromazine hydrochloride can increase prolactin levels in rats. 7-Hydroxychlorpromazine hydrochloride can increase dopamine turnover and has a sedative effect. In addition, 7-Hydroxychlorpromazine hydrochloride can effectively inhibit amphetamine-induced stereotyped behavior in rats and is used in the study of psychosis .

HY-121650

ADTN	Dopamine Receptor	Neurological Disease
ADTN is a dopamine receptor agonist that has the activity of promoting dopamine neurotransmission. ADTN can be used to increase the release of neurotransmitters, thereby improving dopamine-related physiological functions. ADTN's potential applications include inhibiting mental illness and improving cognitive function .

HY-B1834S1

Megestrol-d5	Isotope-Labeled Compounds Progesterone Receptor Glucocorticoid Receptor	Infection Neurological Disease Inflammation/Immunology Cancer
Megestrol-d₅ is the deuterium labeled Megestrol. Megestrol is an orally active glucocorticoid and progesterone receptor agonist. Megestrol can alleviate anorexia, cachexia or unexplained significant weight loss associated with acquired immunodeficiency syndrome (AIDS). Megestrol may cause glucocorticoid-like effects and an increased risk of mental disorders.

Cat. No.	Product Name

HY-L028

CNS-Penetrant Compound Library

1,096 compounds

The blood-brain barrier (BBB) is the complex network of brain microvessels. It protects the brain from the external bloodstream environment and supplies the brain with the required nutrients for normal function. However, blood-brain barrier is also the obstacle to deliver beneﬁcial drugs to treat CNS (central nervous system) diseases or brain tumors, as it has the least permeable capillaries in the entire body due to physical barriers (tight junctions). Therefore, it is crucial to discover drugs which can cross this barrier for the treatment of brain-based diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and epilepsy.

MCE offers a unique collection of 1,096 compounds with confirmed CNS-Penetrant property. It’s a useful tool for the discovery of drugs used for brain diseases, such as brain tumors, mental disorders, and neurodegenerative diseases.

HY-L043

Lipid Compound Library

1,266 compounds

Lipids are a diverse and ubiquitous group of compounds which have many key biological functions, such as acting as structural components of cell membranes, serving as energy storage sources and participating in signaling pathways. Several studies suggest that bioactive lipids have effects on the treatment of some mental illnesses and metabolic syndrome. For example, DHA and EPA are important for monoaminergic neurotransmission, brain development and synaptic functioning, and are also correlated with a reduced risk of cancer and cardiovascular disease in clinical and animal studies.

MCE supplies a unique collection of 1,266 lipid and lipid derivative related compounds including triglycerides, phospholipids, sphingolipids, steroids and their structural analogues or derivatives. MCE lipid compound library can be used for research in bioactive lipids, and high throughput screening (HTS) and high content screening (HCS).

HY-L920

CNS MPO Lead-like Library

24,816 compounds

HY-L919

MCE CNS BBB Lead-like Library

27,503 compounds

With the aging population and increasing competitive pressures, neurodegenerative diseases of the central nervous system (CNS) have become a serious medical challenge in modern society, including Parkinson's disease, Alzheimer's disease, brain tumors, and multiple sclerosis. However, the success rate of CNS drug development remains remarkably low, primarily due to the blood-brain barrier (BBB). The blood-brain barrier (BBB) is a semipermeable barrier structure that surrounds the microvasculature of the CNS. In capillaries, the wedged endothelial cells are tightly packed and wedge-shaped, lining the interior of the vessels to form extensive tight junctions. Along with a range of receptors, transporters, efflux pumps, and other cellular components, this barrier regulates the entry and exit of molecules between the bloodstream and the brain. The intact BBB blocks the passage of most blood-borne substances into the brain, preventing nearly 100% of large-molecule drugs and over 98% of small-molecule drugs from entering. Compared to non-CNS drugs, physicochemical properties such as hydrogen bonds, lipophilicity, and molecular weight significantly influence a compound's ability to cross the BBB. Using artificial intelligence (AI) algorithms to predict BBB permeability, a predicted value greater than 0.75 indicates that the compound has strong potential to cross the BBB, providing a promising starting point for CNS drug discovery.

HY-L102

Rare Diseases Drug Library

1,880 compounds

Rare diseases are an important public-health issue and a challenge for the medical community. Most rare diseases are genetic disorders, which are often severely disabling, substantially affect life expectancy, and impair physical and mental abilities. Currently, there are about 7,000 identified rare diseases, together affecting 10% of the population. However, fewer than 6% of all rare diseases have an approved treatment option, highlighting their tremendous unmet needs in drug development. The process of repurposing drugs for new indications, compared with the development of novel orphan drugs, is a time-saving and cost-efficient method resulting in higher success rates, which can therefore drastically reduce the risk of drug development for rare diseases.

MCE carefully collects a unique of 1,880 compounds studied in preclinical, clinical trials or approved used in rare diseases treatment. MCE rare diseases drug library is a useful tool for the research of rare diseases. All compounds can provide corresponding indications for rare diseases.

HY-L069

Anti-Alzheimer's Disease Compound Library

2,065 compounds

Alzheimer’s Disease (AD) is a progressive degenerative brain disease which causes mental and physical decline, gradually resulting in death. Despite the significant public health issue that it poses, only few medical treatments have been approved for Alzheimer’s Disease (AD) and these act to control symptoms rather than alter the course of the disease. Discovery of new therapeutic approaches depends on the study of pathology of AD. Recent research findings have led to greater understanding of disease neurobiology in Alzheimer's Disease (AD) and identification of unique targets for drug development. Several important mechanisms have been proposed to explain the underlying pathology of AD, such as Amyloid cascade hypothesis, Tau hypothesis and Cholinergic hypothesis, etc.

MCE offers a unique collection of 2,065 compounds with anti-Alzheimer’s Disease activities or targeting the unique targets of AD. MCE Anti-Alzheimer’s Disease Compound Library is a useful tool for exploring the mechanism of AD and discovering new drugs for AD.

Cat. No.	Product Name	Type

HY-W021265

Cyclohexane-1,2,3,4,5,6-hexaol

Cyclohexane-1,2,3,4,5,6-hexol

Biochemical Assay Reagents

Cyclohexane-1,2,3,4,5,6-hexaol, also known as inositol or inositol, is a cyclic sugar alcohol consisting of a six-carbon ring with six hydroxyl groups. This compound is important for its biological activity and is widely distributed in nature, especially in plant and animal tissues. It plays a role in various physiological processes such as signal transduction, osmoregulation and lipid metabolism. In addition, Cyclohexane-1,2,3,4,5,6-hexaol has potential investigational effects, including improving conditions related to insulin resistance, polycystic ovary syndrome, and mental health conditions. It can also be used as a supplement in animal feed and human nutritional products.

HY-W010625

Lithium 2-hydroxypropanoate 35+ Cited Publications	Biochemical Assay Reagents
Lithium 2-hydroxypropanoate is a lithium salt. Lithium 2-hydroxypropanoate has immunomodulatory activity (slightly enhancing PHA (HY-N7038)-induced lymphocyte proliferation). Lithium 2-hydroxypropanoate can be used in antioxidant activity assays. Lithium 2-hydroxypropanoate can be used in the research of mental diseases .

Cat. No.	Product Name	Target	Research Area

HY-P2283

β-Amyloid (1-37) (human)	Amyloid-β	Neurological Disease
β-Amyloid (1-37) (human) correlates moderately with Mini-Mental State Examination (MMSE) scores in Alzheimer disease. β-Amyloid (1-37) (human) possesses an added diagnostic value .

HY-P2204

PD-149163	Neurotensin Receptor	Neurological Disease Inflammation/Immunology
PD-149163 is an NTR-1 agonist. PD-149163 reverses intestinal damage through its anti-inflammatory, antioxidant, and cell proliferation promoting properties. PD-149163 has antipsychotic effects. PD-149163 is commonly used in research on mental illness and intestinal injury .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-W021265

Cyclohexane-1,2,3,4,5,6-hexaol Cyclohexane-1,2,3,4,5,6-hexol	Microorganisms Source Classification	Biochemical Assay Reagents
Cyclohexane-1,2,3,4,5,6-hexaol, also known as inositol or inositol, is a cyclic sugar alcohol consisting of a six-carbon ring with six hydroxyl groups. This compound is important for its biological activity and is widely distributed in nature, especially in plant and animal tissues. It plays a role in various physiological processes such as signal transduction, osmoregulation and lipid metabolism. In addition, Cyclohexane-1,2,3,4,5,6-hexaol has potential investigational effects, including improving conditions related to insulin resistance, polycystic ovary syndrome, and mental health conditions. It can also be used as a supplement in animal feed and human nutritional products.

HY-W010265

Butyrophenone 1-Phenylbutan-1-one; 1-Phenyl-1-butanone	Structural Classification Natural Products Piperaceae Plants Piper nigrum Linn. Source Classification	Environmental Pollutants Dopamine Receptor
Butyrophenone (1-Phenylbutan-1-one) is a dopamine receptor (DA Receptor) antagonist and can be used in research on mental disorders .

HY-N12134

Methyl piperate	Piper longum Linn. Structural Classification Natural Products Piperaceae Plants Source Classification	Monoamine Oxidase
Methylpiperic acid is a piperine alkaloid with significant MAO inhibitory activity (IC₅₀3.6 μM). Methylpiperic acid is less effective against MAO-B (IC 501.6 μM) than MAO-A (IC₅₀27.1 μM) has a bidirectional inhibitory effect. Methylphenidate is used to research mental disorders .

HY-N9628

Polygalatenoside A	Structural Classification Natural Products Polygalaceae Plants Polygala tenuifolia Willd. Source Classification	Adrenergic Receptor
Polygalatenoside A is a noradrenaline reuptake inhibitor with an IC₅₀ of 30.0 μM against human noradrenaline transporter. Polygalatenoside A can be used in the research of mental disorders .

Cat. No.	Product Name	Chemical Structure

HY-B1834S1

Megestrol-d5
Megestrol-d₅ is the deuterium labeled Megestrol. Megestrol is an orally active glucocorticoid and progesterone receptor agonist. Megestrol can alleviate anorexia, cachexia or unexplained significant weight loss associated with acquired immunodeficiency syndrome (AIDS). Megestrol may cause glucocorticoid-like effects and an increased risk of mental disorders.

HY-U00051AS1

(R)-Propiomazine-d6 hydrochloride

(R)-Propiomazine-d₆ hydrochloride is deuterium labeled Propiomazine hydrochloride. Propiomazine hydrochloride is an orally active antihistamine agent. Propiomazine hydrochloride is a potent prolactin (PRL) release stimulant, whose effect depends on the antagonism of the dopaminergic system and can inhibit the secretion of luteinizing hormone (LH). Propiomazine hydrochloride is mainly used for anesthesia assistance, mental disorders and anxiety-induced sedation, and can also be used in research related to insomnia.

HY-U00051AS

Propiomazine-d6 hydrochloride

Propiomazine-d₆ hydrochloride is deuterium labeled Propiomazine hydrochloride. Propiomazine hydrochloride is an orally active antihistamine agent. Propiomazine hydrochloride is a potent prolactin (PRL) release stimulant, whose effect depends on the antagonism of the dopaminergic system and can inhibit the secretion of luteinizing hormone (LH). Propiomazine hydrochloride is mainly used for anesthesia assistance, mental disorders and anxiety-induced sedation, and can also be used in research related to insomnia.

HY-U00051AS2

(S)-Propiomazine-d6 hydrochloride

(S)-Propiomazine-d₆ hydrochloride is deuterium labeled Propiomazine hydrochloride. Propiomazine hydrochloride is an orally active antihistamine agent. Propiomazine hydrochloride is a potent prolactin (PRL) release stimulant, whose effect depends on the antagonism of the dopaminergic system and can inhibit the secretion of luteinizing hormone (LH). Propiomazine hydrochloride is mainly used for anesthesia assistance, mental disorders and anxiety-induced sedation, and can also be used in research related to insomnia.

HY-A0077S2

Perphenazine-d6 fumarate

Perphenazine-d6 (fumarate) is a deuterated labeled Perphenazine . Perphenazine is an orally active dopamine receptor and histamine-1 receptor antagonist, with K_i values of 0.56 nM (D2), 0.43 nM (D3), 6 nM (5-HT2A), respectively. Perphenazine also binds to Alpha-1A adrenergic receptor. Perphenazine inhibits cancer cell proliferation, and induces apoptosis. Perphenazine can be used in the research of mental disease, cancer, inflammation .

HY-100703S

Pipamperone-d10 dihydrochloride

Pipamperone-d₁₀ (Floropipamide-d₁₀) dihydrochloride is a deuterated Pipamperone dihydrochloride (HY-100703A). Pipamperone dihydrochloride (Floropipamide dihydrochloride) is a butyrophenone derivative and high-affinity antagonist of 5-HT_2A receptor (pK_i=8.2) and D₄ receptor (pK_i=8.0). Pipamperone dihydrochloride is also a low-affinity antagonist of D₂ receptor (pK_i=6.7). Pipamperone dihydrochloride affects neurotransmitter functions and exerts antipsychotic activity. Pipamperone dihydrochloride is used in the research of mental disorders such as autism-related behavioral disorders and Alzheimer's disease .

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P86610

	FXR1 Antibody (YA6302) Fragile X mental retardation syndrome-related protein 1; hFXR1p;	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	FXR1 Antibody (YA6302) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to FXR1.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

mental

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

NaturalProducts

Isotope-Labeled Compounds

Antibodies

Natural
Products